Clinical trials: Gastrointestinal Failure
Coronary Artery Disease, Aortic Valve Disorder
Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX
The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards PERIMOUNT Magna Ease Valves in patients undergoing aortic valve replacement with or without concomitant procedures…
- Conditions
- Coronary Artery Disease, Aortic Valve Disorder, Heart Failure, Aortic Valve Stenosis
- Trial name
- NCT01171625
- Testing
- Implantation of CEP Magna Ease Model 3300TFX
- Where
- 13 sites in United States, Austria and 4 more
- Volunteers
- 283 people
- Sponsor
- Edwards Lifesciences
Cirrhosis, Hepatic Encephalopathy
VE303 for Treatment of Hepatic Encephalopathy (HE)
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy.
- Trial name
- NCT04899115
- Testing
- VE303, oral vancomycin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Patricia Bloom
CLABSI - Central Line Associated Bloodstream Infection
Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition
This study an open label prospective observational cohort study to evaluate the safety and efficacy of sodium citrate 4% locking solution in preventing central line associated blood stream infection in children requiring long…
- Trial name
- NCT04756427
- Testing
- Sodium Citrate 4% Inj Syringe 3Ml
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Acute-On-Chronic Liver Failure, Ascites
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and…
- Trial name
- NCT05900050
- Testing
- VS-01 on top of SOC, SOC (Control Group)
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Genfit
Amatoxin Poisoning, Amanita Poisoning
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Legalon® SIL will be administered to patients with amatoxin poisoning diagnosed by history, gastrointestinal symptoms, elevated liver enzymes, and/or diagnostic assay (should one become available).
- Conditions
- Amatoxin Poisoning, Amanita Poisoning, Mushroom Poisoning, Liver Failure
- Trial name
- NCT00915681
- Testing
- Silibinin
- Where
- 2 sites in United States
- Volunteers
- 148 people
- Sponsor
- Mylan Specialty, LP
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Short Bowel Syndrome
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.
- Trial name
- STARSnutrition (NCT04964986)
- Testing
- Apraglutide
- Where
- 2 sites in Belgium, France
- Volunteers
- 10 people
- Sponsor
- VectivBio AG
Idiopathic Short Stature, Failure to Thrive
Ghrelin Levels in Children With Poor Growth
The investigators hypothesize that low serum ghrelin levels may characterize a group of patients with poor weight gain and/or linear growth who do not have any other identified cause for growth failure.
- Trial name
- NCT01070173
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Tripler Army Medical Center
Liver Diseases, Surgery
RESTORE Declined Livers Study
This is a prospective, non-randomized, clinical trial of discarded liver transplants that have received normothermic machine perfusion (NMP), compared with standard cold preservation liver transplants.
- Conditions
- Liver Diseases, Surgery, Transplant; Failure, Liver
- Trial name
- NCT04483102
- Testing
- Declined liver in Normothermic Machine Perfusion (NMP), Standard cold preservation of liver
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Liver Cirrhosis
Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
The study aims to investigate the beneficial effects of fecal transplantation in patients diagnosed with liver cirrhosis (regardless of etiology).
- Trial name
- NCT06478602
- Testing
- Fecal microbiota transplantation
- Where
- Romania
- Volunteers
- 19 people
- Sponsor
- Cristian Ichim
Essential Fatty Acid Deficiency (EFAD)
Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion
This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD).
- Trial name
- NCT02476994
- Testing
- Clinolipid, Intralipid
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baxter Healthcare Corporation
Dementia, Chronic Disease
Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over…
- Conditions
- Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms
- Trial name
- PICSI-H (NCT04283994)
- Testing
- Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
- Where
- 3 sites in United States
- Volunteers
- 756 people
- Sponsor
- University of Washington
Carcinoma
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant…
- Trial name
- EVOLVE-1 (NCT01035229)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 131 sites in United States, Australia and 16 more
- Volunteers
- 546 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Hepatocellular
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
The purpose of this phase III study is to determine whether Doxorubicin Transdrug (DT) is effective in the treatment of patients suffering from advanced Hepatocellular Carcinoma (HCC) after failure or intolerance to Sorafenib.
- Trial name
- ReLive (NCT01655693)
- Testing
- Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care
- Where
- 70 sites in United States, Austria and 9 more
- Volunteers
- 397 people
- Sponsor
- Valerio Therapeutics
Hepatic Encephalopathy, Cirrhosis
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
This study is being done to find out if the laxative polyethylene glycol (also known as GoLYTELY® or Miralax®) can treat your hepatic encephalopathy (confusion due to your liver disease and/or cirrhosis) better and/or more safely…
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Portosystemic Encephalopathy, PSE
- Trial name
- PSE (NCT01283152)
- Testing
- Polyethylene glycol 3350-electrolyte solution (GoLYTELY®), Lactulose
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01210495
- Testing
- Axitinib (AG-013736), Best Supportive Care
- Where
- 77 sites in United States, Belgium and 11 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Hepatitis B, Chronic
Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study
This is a phase IV, single-arm, open-label, multi-centre study to assess the efficacy of TDF in Chronic hepatitis B (CHB) subjects following failure of multiple Nucleos(t)ide analogues (NAs).
- Trial name
- NCT02195518
- Testing
- Tenofovir disoproxil fumarate
- Where
- 12 sites in China
- Volunteers
- 213 people
- Sponsor
- GlaxoSmithKline
Hepatorenal Syndrome
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
This study is designed to evaluate the efficacy and safety of intravenous terlipressin versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in participants receiving standard of care albumin therapy.
- Trial name
- NCT01143246
- Testing
- Terlipressin
- Where
- 73 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Mallinckrodt
Arthritis, Juvenile Rheumatoid, Crohn Disease
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
The investigators hypothesize that the anabolic effects of Genotropin (somatropin) will improve the height and weight of children with inflammatory based chronic illness who have failed to grow despite receiving adequate…
- Trial name
- NCT00511329
- Testing
- somatropin [rDNA origin] for injection
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Nationwide Children's Hospital
Cirrhosis, Hepatic Encephalopathy
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).
- Trial name
- HALT-HE (NCT00999167)
- Testing
- HPN-100
- Where
- 28 sites in United States
- Volunteers
- 189 people
- Sponsor
- Amgen